

<b>REPORT DOCUMENTATION PAGE</b>				Formed Approved MB No.0704-0188	
<p>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</p> <p>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</p>					
1. REPORT DATE (DD-MM-YYYY) 16/06/2004		2. REPORT TYPE Final Report		3. DATES COVERED 01/06/2000 – 14/13/2003	
4. TITLE AND SUBTITLE Reagents and Techniques for Vaccine Development and Immune Response Assessment in California Sea Lions				5a. CONTRACT NUMBER N00014-00-1-0763	
				5b. GRANT NUMBER N00014-00-1-0763	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jeffrey L Stott				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Department of Pathology/Microbiology/Immunology School of Veterinary Medicine University of California Davis, CA 95616			8. PERFORMING ORGANIZATION REPORT NUMBER  ONR		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Office of Naval Research 800 N. Quincy Street Arlington, VA 22217-5000			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION/ AVAILABILITY STATEMENT  Distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The aims of this project were to establish reagents and techniques for (a) the advanced assessment of pathogen-specific immune responsiveness, and (b) the immunogenetic characterization of California sea lions. Monoclonal antibodies specific for sea lion antibody isotypes were developed and characterized; they can now be used to measure antibody responses to vaccines. Cytokine genes were sequenced and this data can now be used to develop quantitative assays for measuring cytokine-specific immune responses to vaccines; cytokines are inducible soluble messengers of the immune response. The major histocompatibility complex (MHC) class I and II genes were cloned and sequenced. Polymorphism was identified in the functionally important MHC class II DRB genes. This polymorphism is an indirect measure of the immunologic vigor of a population. Geographical differences in MHC class II DRB were identified and probably reflect exposure to different environmental influences including different pathogens. Assuming that the geographically unique MHC's identified in this study are due in part to pathogen pressures, Navy animals may be at varying degrees of risk when deployed into waters with free-ranging sea lion populations (i.e. different sea lion pathogens may be active in different geographical locations).					
15. SUBJECT TERMS  marine mammal, immunology, vaccine, California sea lion					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT		18. NUMBER OF PAGES
a. REPORT Unclass	b. ABSTRACT Unclass	c. THIS PAGE Unclass	UL		
					19a. NAME OF RESPONSIBLE PERSON Jeffrey L Stott
					19b. TELEPHONE NUMBER (include area code) 530-752-2543

20040730 028

## **FINAL REPORT**

**GRANT #:** N00014-00-1-0763

**PRINCIPAL INVESTIGATOR:** Dr. Jeffrey L Stott

**INSTITUTION:** University of California

**GRANT TITLE:** Reagents and Techniques for Vaccine Development and Immune Response Assessment in California Sea Lions

**AWARD PERIOD:** June 01, 2000 - March 14, 2003

**OBJECTIVES:** The immediate objectives of this proposal were to: a) establish reagents that can be used to assess the efficacy of vaccination in California sea lions (CSL's) via measurement of post-vaccination cellular (cytokine) and humoral (antibody) immunological responses and b) develop technologies for examining the major histocompatibility complex genotype of CSLs.

**APPROACH:** Monoclonal antibodies specific for CSL antibody isotypes were developed for use in the qualitative and quantitative evaluation of antibody responses following vaccination. CSL cytokine genes were sequenced using degenerate primers. Polymerase chain reaction (PCR) assays were developed for identification of antigen-induced cytokine mRNA production in lymphocytes following vaccination. Major histocompatibility complex genes were analyzed by cloning and sequencing the genes from a large number of CSL's.

**ACCOMPLISHMENTS:** A hybridoma fusion has been completed for the purpose of developing monoclonal antibodies specific for California sea lion immunoglobulin (antibody) isotypes. Seven monoclonal antibodies were characterized with 3 being specific for the IgG, two being specific for the light chain of Ig (bind all antibody isotypes) and two being specific for IgM.

The sequences of two CSL cytokines (IL-10 and IL-12 p40) and 3 dolphin cytokines (IL4, IL-6, IL-10) were amplified and used successfully in quantitative real time RT-PCR assays to measure their expression in phorbol ester-stimulated peripheral blood-derived leukocytes. A bovine system was successfully modified to detect two additional dolphin cytokines (IL-12 and  $\gamma$ -IFN).

Full-length CSL MHC class I and class II genes have been characterized and a novel molecular technique involving a combination of PCR and denaturing gradient gel electrophoresis

(DGGE) has been adapted for rapidly genotyping both CSL class I and CSL class II MHC genes.

Characterization of California sea lion MHC class II genes resulted in identification of three genes with limited polymorphism and questionable function, and a fourth gene, *Zaca-DRB*, that is unique in its high levels of variability, providing evidence of significant effects of pathogen pressures. Moreover, *Zaca-DRB* constitutes a gene family, comprised of at least 8 loci, each exhibiting limited allelic variability, but present in variable configurations among individuals. This unique aspect of sea lion MHC, in addition to the fact that the Navy California sea lions are potentially subject to different pathogen pressures, suggested it would be important to examine the effects of different environmental influences on MHC. Three populations of free-ranging sea lions were studied and genotypic differences identified in MHC between California sea lions inhabiting the Gulf of California and two distinct Pacific Ocean locations. Additionally, genotypic differences were evident among sea lions from closely-located rookeries in the Gulf of California. The differences in MHC genotypes indicated no substantial gene flows between these populations and among nearby rookeries and have implications for potential disease epidemics in this species. An association has been identified between the presence of MHC class II gene loci *Zaca-DRB-A* and cancer, a disease affecting 18 % of sexually mature sea lions necropsied at The Marine Mammal Center in California. The presence of *Zaca-DRB-A* in the genomic repertoire of an individual confers a 3.3 times greater likelihood of getting cancer. Lastly, differential expression of select MHC DRB loci has been identified in both captive and free-ranging California sea lions; these loci-specific perturbations in gene expression may be the result of multiple environmental stressors.

**CONCLUSIONS:** Monoclonal antibodies were developed that can detect apparently all antibodies (light chain-specific), IgG specifically and IgM specifically. Polymerase chain reactions were developed for quantitative evaluation of cytokine mRNA production, specifically,  $\gamma$ -IFN, IL-4, IL-6, IL-10 and IL-12 p40. Both MHC class I and class II genes were characterized and genotyping capabilities developed.

**SIGNIFICANCE:** Development of reagents and techniques for quantitative analysis of CSL antibody and cytokine responses will permit evaluation of prior pathogen exposure and potential vaccine efficacy. The immunogenetic analysis carries considerable implications relative to the deployment of Navy sea lions into national and international waters. Assuming that the geographically unique MHC's identified in this study are due in part to pathogen pressures, Navy animals may be at varying degrees of risk when

deployed into waters with free-ranging sea lion populations (i.e. different sea lion pathogens may be active in different geographical locations).

**PATENT INFORMATION:** None

**AWARD INFORMATION:** None

**PUBLICATIONS & ABSTRACTS:**

**Publications**

Bowen L, BM Aldridge, F Gulland, J Woo, W Van Bonn, R DeLong, JL Stott and ML Johnson. 2003. Molecular characterization of expressed DQA and DQB genes in the California sea lion (*Zalophus Ccalifornianus*). Immunogenetics 54:332-347.

Bowen L, BM Aldridge, F Gulland, W Van Bonn, R DeLong, S Melin, LJ Lowenstine, JL Stott and ML Johnson. 2003. Class II multiformity generated by variable MHC-DRB region configurations in the California sea lion (*Zalophus californianus*). Immunogenetics, 56:12-27.

Bowen L, B Aldridge, R DeLong, F Gulland, L Lowenstine, J Stott, and M Johnson. An immunogenetic basis for the urogenital cancer epidemic of California sea lions (*Zalophus californianus*). Manuscript submitted.

Bowen, L., B. Aldridge, C. Godinez, A. Zavala, L. Lowenstine, S. Melin, R. DeLong, J. Stott, and M. Johnson. MHC gene configuration variation in geographically disparate populations of California sea lion (*Zalophus californianus*): pathogen pressure or breeding biology? Manuscript submitted.

Bowen, L., B. Aldridge, F. Gulland, L.J. Lowenstine, and J.L. Stott. Changes in California sea lion (*Zalophus californianus*) MHC gene expression in the presence of multiple stressors. Manuscript in preparation.

Stott JL, M Hure, B Aldridge and MT Blanchard. Development and characterization of monoclonal antibodies specific for California sea lion immunoglobulins. Manuscript in preparation.

## **Abstracts**

Hure, M, D. P. King, B. M. Aldridge, F. Gulland, W. Van Bonn, M.T. Blanchard & J. L. Stott. "Characterization of Monoclonal Antibodies to California Sea Lion (*Zalophus californianus*) Immunoglobulin Molecules". International Association of Aquatic Animal Medicine, Tampa, FL, 2001.

Funke, C, B Aldridge, C Leutenegger, BR Smith, F Gulland, W Van Bonn and J Stott. Development of a real-time quantitative RT-PCR (TaqMan) assay to measure cytokine profiles in California sea lions (*Zalophus californianus*) and bottlenose dolphins (*Tursiops truncatus*). International Association of Aquatic Animal Medicine, Albufeira, Portugal, 2002.

Bowen, L., B. Aldridge, R. DeLong, L. Lowenstine, J.L. Stott, and M.L. Johnson. Immunogenetic characterization of the California sea lion (*Zalophus californianus*): a framework for future studies. 9<sup>th</sup> International Congress of the International Society for Developmental and Comparative Immunology. St. Andrews, Scotland July, 2003.

Aldridge, B, L. Bowen, B. Smith, G. Antonellis, and J.L. Stott. Molecular characterization of class I MHC genes in pinnipeds: a comparative study. 9<sup>th</sup> International Congress of the International Society for Developmental and Comparative Immunology. St. Andrews, Scotland July, 2003.

Lizabeth Bowen, Brian Aldridge, Robert DeLong, Carlos Godinez, Alfredo Zavala, Linda Lowenstine, Frances Gulland, Jeffrey Stott, and Michael Johnson. Immunogenetic characterization of the California sea lion (*Zalophus californianus*): a framework for future studies. 15<sup>th</sup> Biennial Conference on the Biology of Marine Mammals. Greensboro, North Carolina, December, 2003.

Stott, JL, B Aldridge, L Bowen, M Johnson, L Lowenstine, R DeLong, S Melin, W Van Bonn, T Gelatt, G Antonelis, K Beckmen and K Burek. Diversity of immune response (major histocompatibility complex, MHC) genes in free-ranging pinnipeds. 35<sup>th</sup> Annual Mtg of International Association for Aquatic Animal Medicine, Galveston, Texas, 2004